EyePoint (EYPT) EBT Margin (2010 - 2026)
EyePoint (EYPT) posted EBT Margin of 17277.44% for Q1 2026, down 58.88% sequentially from 10874.68% in Q4 2025, and down 1706309.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) EBT Margin (2010 - 2026) Analysis & Trends
EyePoint has reported EBT Margin for 17 years, with the latest figure at 17277.44% in Q1 2026.
- Quarterly EBT Margin fell 1706309.0% year-over-year to 17277.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4028.09% (down 375345.0% YoY) and the FY2025 annual result came in at 738.53%, down 43631.0% from the prior year.
- EBT Margin slipped to 17277.44% in Q1 2026 per EYPT's latest filing, from 10874.68% in the prior quarter.
- Over five years, EBT Margin peaked at 121.03% in Q4 2023 and troughed at 17277.44% in Q1 2026.
- A 5-year average of 2397.1% and a median of 384.7% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2026: EBT Margin jumped 74030 bps in 2023, then slumped 1706309 bps in 2026.
- Over 5 years, EBT Margin stood at 420.54% in 2022, then surged by 71 bps to 121.03% in 2023, then slumped by 195 bps to 356.48% in 2024, then slumped by 2951 bps to 10874.68% in 2025, then tumbled by 59 bps to 17277.44% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 17277.44%, 10874.68%, and 6183.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -18,633.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18,633.14% |
| Mar 31, 2026 | -12,555.32% |
| Dec 31, 2025 | -10,890.81% |
| Sep 30, 2025 | -6,183.44% |
| Jun 30, 2025 | -1,112.56% |
| Mar 31, 2025 | -200.15% |
| Dec 31, 2024 | -357.34% |
| Sep 30, 2024 | -278.99% |
| Jun 30, 2024 | -325.27% |
| Mar 31, 2024 | -285.42% |
| Dec 31, 2023 | -116.42% |
| Sep 30, 2023 | -94.72% |
| Jun 30, 2023 | -254.77% |
| Mar 31, 2023 | -290.37% |
| Dec 31, 2022 | -421.37% |
| Sep 30, 2022 | -189.86% |
| Jun 30, 2022 | -172.54% |
| Mar 31, 2022 | -210.15% |
| Dec 31, 2021 | -168.38% |
| Sep 30, 2021 | -184.36% |